comparemela.com

Ucla Health Jonsson Comprehensive Cancer Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.

United statesKarim chamieLos angelesUniversity of californiaImmunitybio incBacillus calmetteUcla health jonsson comprehensive cancer centerUrothelial cancer

Dr Konecny on PROs With Mirvetuximab Soravtansine in Advanced Ovarian Cancer

Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.

Los angelesUnited statesGottfried konecnyDepartment of medicineLos angeles healthUniversity of californiaUcla health jonsson comprehensive cancer centerOvarian cancerOnclive tv

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

United statesLos angelesNicholasp mcandrewUniversity of californiaUcla health jonsson comprehensive cancer centerOnclive tvNeoadjuvant her2

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

United statesLos angelesNicholasp mcandrewUniversity of californiaUcla health jonsson comprehensive cancer centerOnclive tvNeoadjuvant her2Breast cancer

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

United statesLos angelesUniversity of californiaRitu salaniGynecologic oncologyUcla health jonsson comprehensive cancer centerOnclive tv

vimarsana © 2020. All Rights Reserved.